S.Biomedics Co., Ltd. (KOSDAQ: 304360)
South Korea
· Delayed Price · Currency is KRW
31,100
+200 (0.65%)
Oct 11, 2024, 9:00 AM KST
S.Biomedics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Oct '24 Oct 10, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 356,856 | 130,376 | - | - | - | - | |
Enterprise Value | 365,197 | 133,226 | - | - | - | - | |
Last Close Price | 31100.00 | 11500.00 | - | - | - | - | |
PE Ratio | - | -16.71 | - | - | - | - | |
PS Ratio | 29.69 | 9.95 | - | - | - | - | |
PB Ratio | 160.36 | 10.62 | - | - | - | - | |
P/FCF Ratio | -61.36 | -16.30 | - | - | - | - | |
P/OCF Ratio | -76.36 | -21.20 | - | - | - | - | |
EV/Sales Ratio | 30.69 | 10.16 | - | - | - | - | |
EV/EBITDA Ratio | -93.48 | -30.03 | - | - | - | - | |
EV/EBIT Ratio | -69.52 | -22.24 | - | - | - | - | |
EV/FCF Ratio | -50.01 | -16.66 | - | - | - | - | |
Debt / Equity Ratio | 1.37 | 0.98 | 13.33 | 1.78 | 1.17 | 0.35 | |
Debt / FCF Ratio | -1.51 | -1.50 | -1.10 | -1.81 | -1.00 | -0.61 | |
Asset Turnover | 0.37 | 0.47 | 0.57 | 0.49 | 0.26 | 0.22 | |
Inventory Turnover | 2.39 | 3.33 | 5.14 | 6.18 | 6.07 | 5.34 | |
Quick Ratio | 1.03 | 1.65 | 0.75 | 3.19 | 1.96 | 2.97 | |
Current Ratio | 1.40 | 2.03 | 0.95 | 3.44 | 2.12 | 3.14 | |
Return on Equity (ROE) | -77.31% | -97.08% | -195.41% | -121.47% | -97.95% | -64.37% | |
Return on Assets (ROA) | -12.90% | -13.30% | -11.13% | -16.13% | -26.13% | -25.05% | |
Return on Capital (ROIC) | -18.03% | -19.15% | -18.41% | -27.49% | -38.11% | -31.69% | |
Earnings Yield | -2.77% | -5.77% | - | - | - | - | |
FCF Yield | -2.05% | -6.13% | - | - | - | - | |
Buyback Yield / Dilution | -9.52% | -6.97% | -0.67% | -0.42% | -3.93% | -406.19% | |
Total Shareholder Return | -9.52% | -6.97% | -0.67% | -0.42% | -3.93% | -406.19% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.